文献速递脑血管病

基底动脉闭塞的血管内取栓治疗:将研究成果转化为临床实践

Endovascular thrombectomy for basilar artery occlusion: translating research findings into clinical practice.
PubMed 文献 · Lancet Neurol · 2023-02-10

基底动脉闭塞是罕见且严重的疾病,早期BASICS和BEST试验未发现血管内取栓在3个月残疾结局方面有显著获益,但提示中重度症状患者可能获益。后续ATTENTION和BAOCHE试验显示,发病24小时内取栓可明确降低残疾和死亡,尤其在中重度症状患者中,颅内出血风险与前循环卒中相似。

要点

  • BASICS和BEST试验未发现取栓在3个月残疾结局有显著获益,但提示中重度症状患者可能获益。
  • ATTENTION和BAOCHE试验显示发病24小时内取栓可明确降低残疾和死亡,尤其在中重度症状患者。
  • 取栓获益不受年龄、基线特征、颅内动脉粥样硬化性疾病及发病至随机化时间影响。

核心结论

  • 对于中重度症状的基底动脉闭塞患者,血管内取栓是否获益的问题现已似乎得到解决,应向符合条件的患者提供血管内取栓。

研究设计与样本

  • 本文为综述,汇总BASICS、BEST、ATTENTION和BAOCHE等血管内取栓治疗基底动脉闭塞的试验证据,并讨论将研究结果转化为临床实践。

主要发现

  • BASICS和BEST试验未发现血管内取栓在卒中后3个月残疾结局方面有显著获益证据,但提示中重度症状患者可能获益。
  • ATTENTION和BAOCHE试验比较发病24小时内血管内取栓与药物治疗,显示取栓在降低残疾和死亡方面有明确获益,尤其在中重度症状患者。
  • 血管内取栓的颅内出血风险与前循环卒中相似。
  • 取栓获益不受年龄、基线特征、颅内动脉粥样硬化性疾病的存在以及症状发作至随机化时间的影响。

临床怎么用

  • 对于中重度症状的基底动脉闭塞患者,应向符合条件的患者提供血管内取栓。

局限性

  • 轻度症状患者取栓的潜在获益尚不明确。
  • 延长时间窗(即症状发作4·5小时之后)静脉溶栓的使用尚不明确。
  • 取栓的最佳血管内技术尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Basilar artery occlusion is a rare and severe condition. The effectiveness of endovascular thrombectomy in patients with basilar artery occlusion was unclear until recently, because these patients were excluded from most trials of endovascular thrombectomy for large-vessel occlusion ischaemic stroke. RECENT DEVELOPMENTS: The Basilar Artery International Cooperation Study (BASICS) and the Basilar Artery Occlusion Endovascular Intervention versus Standard Medical Treatment (BEST) trials, specifically designed to investigate the benefit of thrombectomy in patients with basilar artery occlusion, did not find significant evidence of a benefit of endovascular thrombectomy in terms of disability outcomes at 3 months after stroke. However, these trials suggested a potential benefit of endovascular thrombectomy in patients presenting with moderate-to-severe symptoms. Subsequently, the Endovascular Treatment for Acute Basilar Artery Occlusion (ATTENTION) and the Basilar Artery Occlusion Chinese Endovascular (BAOCHE) trials, which compared endovascular thrombectomy versus medical therapy within 24 h of onset, showed clear benefit of endovascular thrombectomy in reducing disability and mortality, particularly in patients with moderate-to-severe symptoms. The risk of intracranial haemorrhage with endovascular thrombectomy was similar to the risk in anterior circulation stroke. Thrombectomy was beneficial regardless of age, baseline characteristics, the presence of intracranial atherosclerotic disease, and time from symptom onset to randomisation. Therefore, the question of whether endovascular thrombectomy is beneficial in basilar artery occlusion now appears to be settled in patients with moderate-to-severe symptoms, and endovascular thrombectomy should be offered to eligible patients. WHERE NEXT?: Key outstanding issues are the potential benefits of endovascular thrombectomy in patients with mild symptoms, the use of intravenous thrombolysis in an extended time window (ie, after 4·5 h of symptom onset), and the optimal endovascular technique for thrombectomy. Dedicated training programmes and automated software to assist with the assessment of imaging prognostic markers could be useful in the selection of patients who might benefit from endovascular thrombectomy. Large international research networks should be built to address knowledge gaps in this field and allow the conduct of clinical trials with fast and consecutive enrolment and a diverse ethnic representation.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Alemseged F, Nguyen TN, Coutts SB, et al. Endovascular thrombectomy for basilar artery occlusion: translating research findings into clinical practice. Lancet Neurol. 2023. PMID: 36780915. doi:10.1016/S1474-4422(22)00483-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。